CD274 and lung carcinoma: Conversely, immune checkpoint pathways central to lung cancer (PD-1/PD-L1, CTLA-4) show altered ligand/receptor expression during and after SARS-CoV-2 infection, raising conceptual questions about timing and dosing of immunotherapy in patients with recent COVID-19 or persistent immune activation [112,113].